Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥274m2026-01-01 → 2026-06-30StandaloneNet sales
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales (5-year summary)
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Operating income−¥480m2026-01-01 → 2026-06-30StandaloneOperating income
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Ordinary income−¥482m2026-01-01 → 2026-06-30StandaloneOrdinary income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Profit before tax−¥482m2026-01-01 → 2026-06-30StandaloneIncome before income taxes
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Net income−¥483m2026-01-01 → 2026-06-30StandaloneProfit loss
Net income−¥983m2025-01-01 → 2025-12-31StandaloneNet income loss (5-year summary)
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Total assets¥1.9bnat 2026-06-30StandaloneAssets
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.0bnat 2025-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥341mat 2026-06-30StandaloneLiabilities
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2026-06-30StandaloneNet assets
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.4bnat 2026-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash & equivalents¥1.4bnat 2026-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥539m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥4m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥710m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-6.622026-01-01 → 2026-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio81.9%at 2026-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued78,940,200at 2026-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥269m
Drug Discovery And Developmentreportable segmentsegment profit2026-01-01 → 2026-06-30−¥369m
Drug Discovery Supportreportable segmentrevenue2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentrevenue external2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentsegment profit2026-01-01 → 2026-06-30¥159m
Total Of Reportable Segments And Otherssegment totalrevenue2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalrevenue external2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalsegment profit2026-01-01 → 2026-06-30−¥210m
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 430
ItemContextValueUnit
Cash and cash equivalents (5-year summary)Prior1InterimInstant_NonConsolidatedMember1474952000JPY
Cash and cash equivalents (5-year summary)InterimInstant_NonConsolidatedMember1372022000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember1205026000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember78940200
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember81150000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant78940200
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant81150000
Number of shares heldInterimInstant_No1MajorShareholdersMember2380000
Shareholding ratioInterimInstant_No1MajorShareholdersMember0.0301
Number of shares heldInterimInstant_No2MajorShareholdersMember1143500
Shareholding ratioInterimInstant_No2MajorShareholdersMember0.0144
Number of shares heldInterimInstant_No3MajorShareholdersMember1075000
Shareholding ratioInterimInstant_No3MajorShareholdersMember0.0136
Number of shares heldInterimInstant_No4MajorShareholdersMember962700
Shareholding ratioInterimInstant_No4MajorShareholdersMember0.0121
Number of shares heldInterimInstant_No5MajorShareholdersMember843400
Shareholding ratioInterimInstant_No5MajorShareholdersMember0.0106
Number of shares heldInterimInstant_No6MajorShareholdersMember777300
Shareholding ratioInterimInstant_No6MajorShareholdersMember0.0098
Number of shares heldInterimInstant_No7MajorShareholdersMember724500
Shareholding ratioInterimInstant_No7MajorShareholdersMember0.0091
Number of shares heldInterimInstant_No8MajorShareholdersMember700000
Shareholding ratioInterimInstant_No8MajorShareholdersMember0.0088
Number of shares heldInterimInstant_No9MajorShareholdersMember650200
Shareholding ratioInterimInstant_No9MajorShareholdersMember0.0082
Number of shares heldInterimInstant_No10MajorShareholdersMember607000
Shareholding ratioInterimInstant_No10MajorShareholdersMember0.0076
Number of shares heldInterimInstant9863600
Shareholding ratioInterimInstant0.1249
Number of shares issued shares voting rightsInterimInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember22800
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember78902000
Number of voting rights issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember789020
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesLessThanOneUnitMember15400
Number of shares issued shares voting rightsInterimInstant78940200
Number of voting rights issued shares voting rightsInterimInstant789020
Number of shares held in own name treasury shares etcInterimInstant_Row1Member22800
Number of shares held in others names treasury shares etcInterimInstant_Row1Member-
Total number of shares held treasury shares etcInterimInstant_Row1Member22800
Shareholding ratio treasury shares etcInterimInstant_Row1Member0.000
Number of shares held in own name treasury shares etcInterimInstant22800
Number of shares held in others names treasury shares etcInterimInstant-
Total number of shares held treasury shares etcInterimInstant22800
Shareholding ratio treasury shares etcInterimInstant0.000
Cash and depositsPrior1YearInstant_NonConsolidatedMember1205026000JPY
Cash and depositsInterimInstant_NonConsolidatedMember1372022000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember71996000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-12-31pass
balance sheet identitynon_consolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2026-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2026-06-30pass